Sherri Clark
Psychiatric/Mental Health · Dover, DENPI 1366031726
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.0% of the total across 130 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,811, more than ten times the $67 reported in 2023.
Across 130 payments — averaging $21.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$374
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$321
- AbbVie$259
- Corium, LLC$214
- Lundbeck LLC$212
- E.r. Squibb & Sons, L.L.C.$204
- plus $1K from 11 others
What the payments were for
- Food & beverage$2,66596%
- Education$1114%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 23 | $374 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $321 |
| AbbVie | 13 | $259 |
| Corium, LLC | 11 | $214 |
| Lundbeck LLC | 10 | $212 |
| E.r. Squibb & Sons, L.L.C. | 12 | $204 |
| Otsuka America Pharmaceutical, Inc. | 9 | $183 |
| Johnson & Johnson | 6 | $181 |
| Tris Pharma Inc | 10 | $167 |
| Teva Pharmaceuticals USA, Inc. | 3 | $160 |
| Axsome Therapeutics, Inc. | 5 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $100 |
| Vanda Pharmaceuticals Inc. | 4 | $100 |
| Neurocrine Biosciences, Inc. | 4 | $84 |
| Boston Scientific | 2 | $48 |
| Collegium Pharmaceutical, Inc. | 2 | $31 |
| Indivior Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$118
How this compares
$2,776 in reported general payments places this provider in the 85th percentile of 177 psychiatric/mental health providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 44 | $61,490 |
| Invega SustennaPaliperidone Palmitate | 18 | $54,660 |
| RexultiBrexpiprazole | 27 | $40,571 |
| LybalviOlanzapine/Samidorphan Malate | 18 | $28,497 |
| TrintellixVortioxetine Hydrobromide | 55 | $25,702 |
| Aripiprazole | 76 | $16,390 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $14,139 |
| Lurasidone Hcl | 44 | $7,722 |
| Paliperidone ErPaliperidone | 28 | $5,320 |
| Bupropion XlBupropion Hcl | 52 | $3,302 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 15 | $2,794 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 22 | $2,419 |
| Divalproex Sodium ErDivalproex Sodium | 44 | $2,413 |
| Bupropion Hcl SrBupropion Hcl | 91 | $1,569 |
| Oxcarbazepine | 22 | $1,238 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $259 | $61,49044 claims |
| Johnson & JohnsonInvega Sustenna | $181 | $54,66018 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $183 | $40,57127 claims |
| Alkermes, Inc.Lybalvi | $374 | $28,49718 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $100 | $25,70255 claims |
| Axsome Therapeutics, Inc.Auvelity | $121 | $14,13912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 177 psychiatric/mental health providers in Delaware.
Other psychiatric/mental health in Dover
- Ericka Taylor-DanielDover$39K
- Cindy CunninghamDover$14K
- Jeremy LegatesDover$3K
- Melchizedec BosireDover$3K
- Maureen DarlingDover$3K
- Heather FryeDover$3K
- Morgan WebbDover$2K
- Ronald TyreeWilmington$59K
- Kameka HartNewark$10K
- Jenika MilesWilmington$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.